Altitude Life Science Ventures seeks opportunities to invest in early stage life science companies within markets with significant demand and growth potential, and then backs the highest-quality teams in those markets to build defensible, strong, and long-term businesses. Their scope of investment opportunities extends beyond prescription drugs to any commercial application of proprietary technology that originates from a key advance in biology or chemistry.

Venture Capital

Altitude Life Science Ventures

Kristen joined [Altitude Life Science Ventures](/org/alsv) in 2015. Prior to Altitude, she worked at Bayer HealthCare where she was responsible for high level project management activities for the commercialization of two pipeline drugs with expenditures totaling more than $150M. These activities included a high priority project to collect and analyze issues pertaining to the commercial manufacturing process and to ensure follow-through and close-out of critical activities. Disciplined adherence to these tight timelines, communication with cross-functional teams, and resolution of complex issues were of upmost importance to ensure that these drug products remained within company timelines for FDA submission and licensure. Kristen has also held roles as a Conformance Investigator and Process Development Scientist. She holds a MBA from University of North Carolina Kenan-Flagler Business School and undergraduate and Master’s degrees in Biology from Stanford University. Her specific areas of interest include minimally invasive medical devices, nanorobotics, and the application of artificial intelligence to the healthcare arena. She is also a registered patent agent (USPTO Registration No. 79,212). 



Kristen Wong

Dave has been associated with life science organizations for over 30 years and co-founded [Altitude Life Science Ventures](/org/alsv) in 2005.  Prior to founding Altitude, he served as a Partner with Perennial Ventures and as a Vice President with Tredegar Investments.  From 1987 to 1999, he served as a Partner at the intellectual property firm of Seed and Berry (now Seed IP Law), where he focused on strategic planning for healthcare companies, particularly in relation to R&D planning, competitive analysis, and corporate collaborations and licensing transactions. During the latter portion of his 17 year tenure at the firm, Dave served in the roles of Managing Partner and Financial Partner. Under his leadership as Senior Partner in the Biotechnology Group, the firm built a client base of over 60 healthcare companies. Dave currently serves as a Director on the Board of Effector Therapeutics, and previously served as Director on the Board of Omniome and as Chairman of the Board of the Infectious Disease Research Institute.



Dave Maki

Altitude Life Science Ventures' Leadership Team includes Kristen Wong and 1 others.

Leadership Team

About

Team members

Discover similar companies